Osteosarcoma | CHOP Research Institute


This study involves an investigational cellular therapy called Afamitresgene Autoleucel.

This study enrolls patients that have been diagnosed with osteosarcoma or neuroblastoma that has come back (relapsed) or has not responded to standard treatments (refractory).

This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory").

This study involves a taking a study drug called vactosertib by mouth.
Published on
Nov 16, 2023
The Connor Initiative, a multimillion dollar gift from the Holveck Family, will support precision therapeutics for osteosarcoma and rare cancers.

The Mitochondria and Cancer Connections (MC2) Research program leverages knowledge from existing centers to establish a novel, cutting-edge research initiative and enable the development of mechanistic understanding and novel therapeutic opportunities at the intersection of mitochondrial disease and pediatric cancer.

Published on
Sep 22, 2023
Dr. Patrick Grohar will lead a research team to bring new therapies to clinical trial.

This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy.

Published on
Sep 22, 2021
Marni Falk, MD, and Adam Resnick, PhD, to lead the Mitochondria and Cancer Connections (MC²) Research Program, a new CHOP research initiative.
weberk [at] chop.edu